Bluebird bio Inc [NASDAQ: BLUE] price plunged by -0.61 percent to reach at $0.0.
The one-year BLUE stock forecast points to a potential upside of 83.67. The average equity rating for BLUE stock is currently 2.80, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Bluebird bio Inc [BLUE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLUE shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLUE stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Bluebird bio Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 15, 2024. The new note on the price target was released on December 11, 2023, representing the official price target for Bluebird bio Inc stock. Previously, the target price had yet another raise from $3 to $7, while Morgan Stanley kept a Equal-Weight rating on BLUE stock.
The Average True Range (ATR) for Bluebird bio Inc is set at 0.03, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 1.73. The Price to Book ratio for the last quarter was 1.79, with the Price to Cash per share for the same quarter was set at 0.75.
BLUE Stock Performance Analysis:
Bluebird bio Inc [BLUE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.66. With this latest performance, BLUE shares gained by 3.85% in over the last four-week period, additionally sinking by -46.24% over the last 6 months – not to mention a drop of -82.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 43.52, with the RSI for the last a single of trading hit 44.92, and the three-weeks RSI is set at 42.06 for Bluebird bio Inc [BLUE]. The present Moving Average for the last 50 days of trading for this stock 0.5354, while it was recorded at 0.4909 for the last single week of trading, and 0.9559 for the last 200 days.
Insight into Bluebird bio Inc Fundamentals:
Bluebird bio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.57 and a Current Ratio set at 0.68.
BLUE Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLUE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bluebird bio Inc go to 45.80%.
Bluebird bio Inc [BLUE] Institutonal Ownership Details
There are presently around $43.90%, or 44.14%% of BLUE stock, in the hands of institutional investors. The top three institutional holders of BLUE stocks are: BLACKROCK INC. with ownership of 15.44 million shares, which is approximately 14.1544%. VANGUARD GROUP INC, holding 10.3 million shares of the stock with an approximate value of $$10.14 million in BLUE stocks shares; and VANGUARD GROUP INC, currently with $$6.29 million in BLUE stock with ownership which is approximately 5.8586%.
